消息面上，11月以来，全国流感活动快速上升，北京已迈入呼吸道传染病高发期。有数据显示，奥司他 韦近7天销量暴涨237%，速福达（玛巴洛沙韦）涨幅达180%，美团买药平台数据更显示，11月以来北 京甲乙流特效药环比增长超130%，其中速福达增长超110%，磷酸奥司他韦颗粒增长超85%。另据阿里 健康平台数据，近两周（11月10日—11月23日）流感应季药品的关注度和购买量均有明显提升，其中流 感抗病毒药物购买人数呈现超500%的环比增长。 机构表示，近期流感活动度持续攀升，当前已攀升至近2022年以来同期高位，流感用药需求增加，关注 流感高发带来的呼吸系统用药需求增长。 生物疫苗概念25日盘中震荡走高，截至发稿，金迪克20%涨停，华兰疫苗涨超10%，海南海药亦涨停， 一品红涨超9%，以岭药业涨逾5%。 ...

Core Insights - The flu season has arrived earlier than expected, leading to increased activity in flu-related stocks in the A-share market [1] - Significant sales increases have been reported for antiviral medications, with Oseltamivir sales up 237% and Mabalaosavir up 180% in the past week [1] Stock Performance - Notable stock movements include: - Yipinhong (一品红) up 13% - Hendi Pharmaceutical (亨迪药业) up nearly 11% - Special One Pharmaceutical (特一药业) and Guangji Pharmaceutical (广济药业) both hitting the 10% daily limit up - Other companies like Hainan Haiyao (海南海药) and Peking University Pharmaceutical (北大医药) also saw significant gains [1][2] - The overall market sentiment is positive, with many flu-related stocks experiencing substantial year-to-date increases, such as: - Yipinhong with a year-to-date increase of 225.09% - Hainan Haiyao with a 75.37% increase [2] Consumer Behavior - Data from Alibaba Health indicates a marked increase in the attention and purchase volume of flu medications over the past two weeks, with a more than 500% week-on-week growth in the number of buyers for antiviral drugs [1] - Mabalaosavir has shown exceptional performance, with a 600% increase in the number of buyers compared to the previous period, reflecting heightened consumer awareness regarding flu prevention and treatment [1]

以下文章来源于证券之星 ，作者刘凤茹 证券之星 . 证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。 来源｜证券之星 作者｜刘凤茹 当前，全国正经历一个明显的流感高发季，活动水平陡升，南方地区尤为严重。作为预防流感最经济有效的手段，流感疫苗需求激增。这一公共卫生 事件迅速传导至市场，导致广州、西安、常州、济南等多地社区卫生服务中心出现流感疫苗"阶段性紧张"甚至缺货的现象。 需求旺盛下，行业龙头华兰疫苗(301207.SZ)因拥有年产1亿剂的产能，并在近期加快了批签发速度引发关注。市场也给予热烈回应，公司股价在一 个多月内区间涨幅超过30%。 证券之星注意到，供需两旺的表象之下，暗藏华兰疫苗业绩"寒意"：今年前三季度，公司营收与归母净利润双双大幅下滑，降幅分别达15.81%和 50.51%，呈现"越卖越亏"的尴尬局面。 这背后，始于2024年中的行业"价格战"。华兰疫苗曾期望"以价换量"稳住规模，但现实是"价"降"量"未足，毛利率和净利率显著下滑。当下需求高 峰中，华兰疫苗能否将短暂的市场需求转化为实实在在的业绩回暖，要打上一个问号。 01 流感疫苗出现阶段 ...

Core Insights - Hualan Vaccine's stock price decreased by 2.02% on November 20, trading at 22.34 CNY per share with a market capitalization of 13.43 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.63%, but a recent decline of 5.62% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Hualan Vaccine reported a revenue of 806 million CNY, a year-on-year decrease of 15.81%, and a net profit attributable to shareholders of 132 million CNY, down 50.51% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.037 billion CNY, with 957 million CNY distributed over the past three years [3] Shareholder Structure - As of October 20, 2025, the number of shareholders for Hualan Vaccine stands at 17,000, with an average of 35,332 circulating shares per person [2] - The top ten circulating shareholders include notable entities such as the China Southern Asset Management Co., which has reduced its holdings by 43,990 shares [3]

Core Insights - The Biotech Index (970038) closed at 2182.31 points, down 0.94%, with a trading volume of 13.462 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 7 stocks rose while 42 stocks fell, with Xinlitai leading the gainers at 0.83% and Hualan Biological leading the decliners at 5.98% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price at 204.81, and a decline of 0.92% [1] - Changchun High-tech (sz000661) with a weight of 4.87%, latest price at 102.32, and a decline of 0.27% [1] - Shimeiao (sz002252) with a weight of 4.74%, latest price at 6.70, and a decline of 0.30% [1] - Kanglong Chemical (sz300759) with a weight of 4.55%, latest price at 29.16, and a decline of 1.22% [1] - Tigermed (sz300347) with a weight of 4.54%, latest price at 52.37, and a decline of 2.44% [1] - Shenzhen Technology (sz000021) with a weight of 4.16%, latest price at 23.90, and a decline of 1.77% [1] - Muyuan Foods (sz002714) with a weight of 3.62%, latest price at 48.45, and a decline of 0.31% [1] - Lepu Medical (sz300003) with a weight of 3.19%, latest price at 16.11, and a decline of 1.29% [1] - Aimeike (sz300896) with a weight of 3.16%, latest price at 155.51, and an increase of 0.58% [1] - Yuyue Medical (sz002223) with a weight of 3.07%, latest price at 35.28, and a decline of 0.20% [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 1.382 billion yuan from major funds, while retail investors saw a net inflow of 1.358 billion yuan [1] - Notable capital flows include: - Aimeike (sz300896) had a net inflow of 26.5772 million yuan from major funds, but a net outflow from retail investors of 20.4422 million yuan [2] - Changchun High-tech (sz000661) saw a net inflow of 8.8418 million yuan from major funds, with a slight net inflow from retail investors of 186.25 thousand yuan [2] - Other stocks like Furuisi (sz300049) and Yuyue Medical (sz002223) also showed mixed capital flows with significant net outflows from retail investors [2]

Core Insights - The biopharmaceutical sector experienced a decline of 0.98% on November 18, with He Yuan Bio leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance Summary - Notable gainers included: - Aopu Mai (688293) with a closing price of 58.80, up 3.38% on a trading volume of 15,900 shares and a transaction value of 93.39 million [1] - Jin Hu Ke (688670) at 26.80, up 2.88% with a volume of 116,300 shares and a transaction value of 319 million [1] - Te Bao Bio (688278) at 77.08, up 1.22% with a volume of 10,800 shares and a transaction value of 82.57 million [1] - Notable decliners included: - Bu Yuan Bio (688765) at 79.95, down 3.89% with a volume of 56,800 shares and a transaction value of 458 million [2] - San Sheng Guo Jian (688336) at 67.60, down 3.87% with a volume of 68,100 shares and a transaction value of 469 million [2] - Wo Wu Bio (300357) at 31.77, down 3.23% with a volume of 77,900 shares and a transaction value of 250 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 981 million from institutional investors, while retail investors contributed a net inflow of 819 million [2] - Key stocks with significant capital flow included: - Hua Lan Vaccine (301207) with a net inflow of 48.51 million from institutional investors [3] - Rong Chang Bio (688331) with a net inflow of 23.62 million from institutional investors [3] - Jin Ke (688670) with a net inflow of 5.53 million from institutional investors [3]

Core Points - The Bioeconomy Index (970038) closed at 2213.22 points on November 17, down 1.73% with a trading volume of 19.985 billion yuan and a turnover rate of 1.43% [1] - Among the index constituents, 7 stocks rose while 42 stocks fell, with Jingxin Pharmaceutical leading the gainers at 4.2% and Hualan Biological leading the decliners at 5.4% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price at 206.04, down 0.80%, total market value of 249.811 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 4.87%, latest price at 102.16, down 2.29%, total market value of 41.675 billion yuan [1] - Ten Years Aoshi (sz002252) with a weight of 4.74%, latest price at 6.82, down 0.73%, total market value of 45.271 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.55%, latest price at 29.80, down 5.34%, total market value of 52.990 billion yuan [1] - Tigermed (sz300347) with a weight of 4.54%, latest price at 55.58, down 4.01%, total market value of 47.856 billion yuan [1] - Deep Technology (sz000021) with a weight of 4.16%, latest price at 24.56, down 0.73%, total market value of 38.600 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.62%, latest price at 48.46, down 2.83%, total market value of 264.726 billion yuan [1] - Lepu Medical (sz300003) with a weight of 3.19%, latest price at 16.32, down 2.74%, total market value of 30.084 billion yuan [1] - Aimeike (sz300896) with a weight of 3.16%, latest price at 155.95, down 1.05%, total market value of 47.189 billion yuan [1] - Sequoia Medical (sz002223) with a weight of 3.07%, latest price at 35.59, down 1.71%, total market value of 35.678 billion yuan [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 1.896 billion yuan from institutional investors, while retail investors saw a net inflow of 1.536 billion yuan [1] - The detailed capital flow for selected stocks includes: - Huace Testing (300012) with a net inflow of 25.405 million yuan from institutional investors [2] - Jingxin Pharmaceutical (002020) with a net inflow of 21.781 million yuan from institutional investors [2] - Pro Pharmaceutical (000739) with a net inflow of 4.350 million yuan from institutional investors [2] - Meiya Optoelectronics (002690) with a net inflow of 3.279 million yuan from institutional investors [2] - Kairui Medical (300633) with a net inflow of 3.268 million yuan from institutional investors [2]

Group 1 - The core point of the news is that Hualan Vaccine's stock is currently trading at 24.01 yuan, reflecting a decline of 5.40% and is in a state of breaking its initial public offering price [1] - Hualan Vaccine was listed on the Shenzhen Stock Exchange's ChiNext on February 18, 2022, with an initial public offering price of 56.88 yuan per share and a total of 40.01 million shares issued [1] - The stock reached its highest point of 79.78 yuan on the first day of trading but has since experienced a downward trend [1] Group 2 - The total amount raised from the initial public offering was 2.276 billion yuan, with a net amount of 2.244 billion yuan after deducting issuance costs of 31.5657 million yuan [1] - The actual funds raised were 251 million yuan less than the planned amount of 2.495 billion yuan, which was intended for various vaccine development and production projects [1] - The total issuance costs amounted to 31.5657 million yuan, with Huatai United Securities receiving a total of 22 million yuan in underwriting and sponsorship fees [1] Group 3 - On May 30, 2023, Hualan Vaccine announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 5 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for June 6, 2023, with the ex-dividend date on June 7, 2023 [2]

Core Insights - Hualan Biological Engineering experienced a 5% drop in stock price, trading at 24.11 CNY per share with a total market capitalization of 14.491 billion CNY as of November 17 [1] Company Overview - Hualan Biological Engineering Co., Ltd. is located in Xinxiang, Henan Province, established on November 9, 2005, and listed on February 18, 2022. The company primarily focuses on the research, production, and sales of human vaccines, with 98.11% of its revenue derived from vaccine products and 1.89% from other sources [1] Shareholder Analysis - Among the top ten circulating shareholders of Hualan Biological, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 8,700 shares in the third quarter, now holding 1.6522 million shares, which represents 0.28% of the circulating shares. The estimated floating loss today is approximately 2.0983 million CNY [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a current scale of 76.63 billion CNY. Year-to-date returns are 27.45%, ranking 1919 out of 4216 in its category, while the one-year return is 21.12%, ranking 2025 out of 3956. Since inception, the fund has returned 12.79% [2] - The fund manager, Cui Lei, has been in the position for 7 years and 12 days, managing assets totaling 122.76 billion CNY, with the best fund return during the tenure being 181.49% and the worst being -15.93% [2]

Core Insights - The avian influenza concept sector saw an increase of 1.21%, ranking 10th among concept sectors, with 16 stocks rising, including Zhongsheng Pharmaceutical which hit the daily limit, and Hualan Vaccine, Kangyuan Pharmaceutical, and Yiling Pharmaceutical showing notable gains of 7.22%, 4.53%, and 3.14% respectively [1][2] Group 1: Stock Performance - Zhongsheng Pharmaceutical led the sector with a net inflow of 7.32 billion yuan, while Kangyuan Pharmaceutical, Yiling Pharmaceutical, and Hualan Vaccine also experienced significant net inflows of 3274.76 million yuan, 3130.43 million yuan, and 2904.55 million yuan respectively [2][3] - The top gainers in the avian influenza concept included Zhongsheng Pharmaceutical with a daily increase of 9.98%, followed by Hualan Vaccine at 7.22%, and Kangyuan Pharmaceutical at 4.53% [3][4] Group 2: Market Trends - The avian influenza concept sector attracted a net inflow of 6.66 billion yuan today, with 10 stocks receiving net inflows, and 6 stocks exceeding 10 million yuan in net inflow [2] - The net inflow ratios for leading stocks were 36.05% for Zhongsheng Pharmaceutical, 8.22% for Dongfang Bio, and 7.21% for Rhine Bio, indicating strong investor interest in these companies [3][4]